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Alessan dra Mangia 
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S. Giovanni Rotondo , Italy To the Editor:
We read with interest the paper publish ed by Dr. Foster and co- 
authors [1]. As clearly stated in the manuscript, irrespecti ve of
the previous deﬁnition of response, the overall SVR rates at week 
4, after Lead-In phase (LI), were 33% in those with <1 log decline 
and 82% in the subset with >1 log decline, respectivel y. Multiple 
logistic regression analysis conﬁrmed that LI is a strong indepen- 
dent predictor of SVR (OR 5.1, 95% CI 2.6–10.1). This ﬁnding
enhances the concept that the degree of interferon sensitivi ty
plays a major role in modulating the efﬁcacy of ﬁrst generation 
protease inhibitors. Despite this result, the data provided by this 
study did not fully assess the potential usefulness of LI phase in
the context of triple therapy with telaprevir (TVR), because they 
lack to further detail the effect of LI according to the ﬁbrosis
stage. Along this line, it also should be taken into account that 
patients with advanced ﬁbrosis/cirrhosis represent, in real life,
the majority of those to deal with for re-treatmen t, and missing 
or unreliable data on virologic on-therapy response during previ- 
ous treatment is common.
In previous subanalys es carried out in the Realize study [2,3],
the overall SVR rates in null and partial responders with cirrhos is
(Metavir F4) were 14% and 34% (pooled TVR arms), respectively .
More recently, the same group of investig ators also reported that 
the proportion of patien ts with cirrhos is increased from relapsers 
to null respond ers, whatever the response after 4 weeks of ther- 
apy [5]. Considering this result, a further decrease of response 
rate across the prior failure categories, accordin g to the presence 
of a more severe liver damage, should be suspected. Regrettabl y,
in these reports, SVR rates accordi ng to ﬁbrosis stages and LI were 
not illustrated. In the same way, of main interest, the present 
paper missed to provide the rate of SVR in F4 patien ts who had 
less than 1 log decline after LI (overall and accordin g to their prior 
deﬁnition of response). This informatio n, by contrast, was 
recently stated for boceprevi r (BOC, SPRINT 2 and RESPOND 2
combined) [4].
To date, while waiting for more effective molecules that will 
eliminate the need of IFN, a detailed analysis of week 4 response 
by severity of liver damage represents a no longer deferrable 
unmet clinical need. Using this informatio n, both Scientiﬁc Com- 
munity and Clinicians worldwide could better determine the util- 
ity of LI in assessing the risk/beneﬁt of treatment in cirrhotic 
patients with either BOC or TVR triple combin ation therapy [6,7].Journal of Hepato logy 20Conﬂict of interest 
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